FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

For research purposes only. Full disclaimer →

مكتبة البروتيدات

MOTS-c

Mitochondrial Open Reading Frame of the 12S rRNA Type-c

Longevity & Anti-Aging

MOTS-c (Mitochondrial Open reading frame of the Twelve S rRNA type-c) is a 16-amino acid mitochondrial-derived peptide (MDP) encoded within the mitochondrial 12S rRNA gene, discovered by Changhan David Lee's laboratory at the University of Southern California in 2015. It is the first mitochondrial-encoded peptide demonstrated to have systemic hormonal signaling functions, acting as an exercise mimetic that regulates metabolic homeostasis through AMPK activation and nuclear genome communication. MOTS-c represents a paradigm-shifting discovery revealing mitochondria as endocrine organelles capable of producing signaling molecules that regulate whole-body metabolism.

mechanism of action

Mitochondria-derived peptide encoded by the 12S rRNA gene. Acts as an exercise mimetic by activating AMPK and regulating the folate-methionine cycle. Improves insulin sensitivity, reduces fat accumulation, and enhances cellular stress resistance.

Research Protocols

للاستخدام البحثي فقط. ليس مشورة طبية.

Research protocols use 5-10mg subcutaneously 3-5 times weekly. Some protocols use daily dosing at 5mg. Cycles of 4-8 weeks. Often combined with exercise protocols.

Research Notes

Clinical Research Status

MOTS-c remains in preclinical research stages with no human clinical trials registered as of 2024, though its discoverer has established extensive in vivo efficacy data in murine models. The peptide's discovery in 2015 at USC Leonard Davis School of Gerontology opened an entirely new field of mitochondrial-derived peptide biology. Research applications focus on metabolic syndrome, type 2 diabetes, obesity, exercise intolerance, and aging-related metabolic decline. Several pharmaceutical groups are evaluating MOTS-c analogs for clinical development targeting metabolic diseases.

Key Published Findings

The landmark 2015 Cell Metabolism paper demonstrated MOTS-c prevents age-dependent and high-fat diet-induced insulin resistance in mice through AMPK pathway activation. A 2016 study showed exercise acutely increases circulating MOTS-c levels in humans, and that MOTS-c translocates to the nucleus during metabolic stress to regulate adaptive gene expression. Research published in 2019 demonstrated that Japanese centenarian populations carry a specific MOTS-c polymorphism (m.1382A>C) at significantly higher frequencies than age-matched controls, suggesting a longevity association. MOTS-c has been shown to increase fatty acid beta-oxidation, improve glucose uptake independent of insulin, and regulate the folate-methionine cycle.

Safety Profile

No formal toxicology studies have been published, though animal studies using therapeutic doses have reported no adverse effects on organ histology, behavior, or reproductive function. As an endogenous peptide naturally produced by human mitochondria, the theoretical safety profile is favorable compared to synthetic xenobiotic compounds. The peptide is degraded by standard proteases with a short plasma half-life, reducing accumulation risk. Long-term safety data in humans is entirely absent, representing the primary unknown in its risk profile.

Drug Interactions & Contraindications

MOTS-c's AMPK activation mechanism suggests potential interactions with metformin and other AMPK activators (AICAR, berberine), possibly producing additive or synergistic metabolic effects. Patients on insulin or sulfonylureas should monitor blood glucose closely as MOTS-c may enhance glucose disposal and increase hypoglycemia risk. Theoretical concern exists regarding concurrent use with mitochondrial-targeted drugs or supplements (CoQ10, NAD+ precursors) as the combinatorial effects on mitochondrial signaling are unknown. Not recommended in patients with mitochondrial diseases as the altered mitochondrial genome context may produce unpredictable effects.

Comparison to Related Compounds

MOTS-c is one of several mitochondrial-derived peptides (MDPs) including humanin and SHLP1-6, but is unique in its metabolic rather than cytoprotective primary function. Unlike metformin (which also activates AMPK), MOTS-c is an endogenous signaling peptide that regulates the nuclear genome through retrograde mitochondrial communication. Compared to GLP-1 agonists for metabolic disease, MOTS-c acts through fundamentally different mechanisms (AMPK vs. incretin pathway) and does not cause nausea or GI effects. Its exercise-mimetic properties distinguish it from other metabolic peptides, directly recapitulating molecular signatures of physical training.

Community Observations

Users typically dose MOTS-c at 5-10 mg subcutaneously, 2-5 times per week, often in conjunction with exercise to potentially amplify training adaptations. Reports suggest improved exercise endurance, faster metabolic rate, and enhanced body composition changes when combined with training programs. Some users describe noticeable improvements in fasting glucose levels and insulin sensitivity within 2-4 weeks. The peptide is considered experimental by most in the community given the absence of human clinical data, and is often used by those interested in longevity research and mitochondrial optimization.

Half Life

~4-8 hours

Reconstitution

Bacteriostatic water (BAC)

Storage

Lyophilized

Refrigerate 2-8C up to 12 months.

Reconstituted

Refrigerate 2-8C. Use within 14 days.

US Legal Status

Research chemical (not FDA-approved)

Also Known As

Mitochondrial Open Reading Frame of the 12S rRNA Type-c

الأسئلة الشائعة

ما هو MOTS-c؟

MOTS-c (Mitochondrial Open reading frame of the Twelve S rRNA type-c) is a 16-amino acid mitochondrial-derived peptide (MDP) encoded within the mitochondrial 12S rRNA gene, discovered by Changhan David Lee's laboratory at the University of Southern California in 2015. It is the first mitochondrial-encoded peptide demonstrated to have systemic hormonal signaling functions, acting as an exercise mimetic that regulates metabolic homeostasis through AMPK activation and nuclear genome communication. MOTS-c represents a paradigm-shifting discovery revealing mitochondria as endocrine organelles capable of producing signaling molecules that regulate whole-body metabolism.

كيف يعمل MOTS-c؟

Mitochondria-derived peptide encoded by the 12S rRNA gene. Acts as an exercise mimetic by activating AMPK and regulating the folate-methionine cycle. Improves insulin sensitivity, reduces fat accumulation, and enhances cellular stress resistance.

ما هو الوضع التنظيمي لـ MOTS-c في الولايات المتحدة؟

Research chemical (not FDA-approved)

ما هو عمر النصف لـ MOTS-c؟

~4-8 hours

ما الأسماء الأخرى لـ MOTS-c؟

Mitochondrial Open Reading Frame of the 12S rRNA Type-c

Peptide Contacts provides research-based summaries for informational purposes only. We do not host, distribute, or endorse vendor documentation. All certificates of analysis, GMP certificates, and vendor communications must be requested and verified directly by the buyer. Nothing on this platform constitutes legal, medical, or professional advice. Users are solely responsible for verifying vendor credentials and ensuring compliance with all applicable local, state, and federal laws before purchasing any research chemicals. Use of this platform constitutes acceptance of full personal responsibility.

Read full disclaimer